The Cost of Inpatient Care of Schizophrenia in the Polish and Ukrainian Academic Centers—Poznan and Lviv by Tomasz Zaprutko et al.
EMPIRICAL REPORT
The Cost of Inpatient Care of Schizophrenia in the Polish
and Ukrainian Academic Centers—Poznan and Lviv
Tomasz Zaprutko & Elżbieta Nowakowska &
Krzysztof Kus & Rostyslav Bilobryvka &
Lyudmyla Rakhman & Andrzej Pogłodziński
Received: 16 April 2014 /Accepted: 23 June 2014 /Published online: 13 September 2014
# The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract
Objective The authors aimed to analyze and compare treat-
ments of schizophrenia in Poznan and Lviv to present the
potential differences between Poland and Ukraine in pharma-
cotherapy and economic availability of medicines, to empha-
size the role of academic centers in the effective treatment of
schizophrenia, and to raise the awareness of residents about
economics and the cost of inpatient care.
Methods The analysis was based on 307 hospital records of
patients treated in 2010 and 2011 and data from the hospital
accounting department. Per the inclusion criteria, 108 adult
patients (50 in Poznan and 58 in Lviv) were enrolled in the
study. Monetary values were converted into euros (EUR) at
the rate published by the National Bank of Poland (NBP) on
October 9, 2012.
Results The total cost of schizophrenia treatment in Poznan
was EUR 160,489.26, x=EUR 3,209.78 per patient, and in
Lviv it was EUR 30,943.38, x=EUR 533.5 per patient. Treat-
ment schedules differed between Poznan and Lviv, and phar-
macotherapy was limited economically, especially in Lviv.
Conclusion Although the results differ between Poznan and
Lviv, the study shows that schizophrenia treatment is expen-
sive in both centers. Differences in the health care systems
make use of innovative neuroleptics unavailable especially in
Lviv, which may contribute to non-compliance or higher level
of relapses. Distinctive efforts to improve therapies should be
made and efforts to equalize access to innovative pharmaco-
therapy should be supported to improve the therapy’s efficacy
and the economic values of schizophrenia treatment.
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Mental disorders are increasingly often considered in terms of
social problems, and mental health is believed to be one of the
most important resources of a modern person [1]. The Euro-
pean Commission, in the Green Paper prepared in 2005,
indicates the mental health of European Union (EU) citizens
as one of the conditions to achieve strategic objectives of the
European Union policy, such as a significant improvement of
the quality of life of the EU’s population, to ensure social
justice and tolerance, and to put Europe back on the path to
sustained economic stabilization [2].
Changing style and pace of life, coexisting stress, and the
pressure of excess duties or job loss put the mental health of
many people to trials with which they are unable to cope [1].
An estimated one in four adult Europeans experiences symp-
toms of one of the mental disorders within a year [2, 3]. Poor
mental health of EU citizens, meanwhile, costs the EU ap-
proximately 3–4 % of its gross domestic product (GDP),
mainly due to lost productivity [2, 4].
Among the mental disorders, schizophrenia is one of the
most serious and disabling, and despite marginalization in
many social groups, according to the World Health Organiza-
tion (WHO), schizophrenia affects approximately 24 million
people worldwide [5, 6]—in the USA, 2 million adults suffer
from this disorder [1]. Schizophrenia is a chronic disorder
requiring long-standing treatment and having a significant
impact on patients and their families [7]. Its onset generally
occurs in early adulthood [1] and, apart from the health conse-
quences, schizophrenia generates high direct and indirect costs,
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such as the cost of hospitalization, pharmacotherapy, diagnos-
tic tests, and loss of productivity [8]. WHO assesses that
direct costs of schizophrenia account for between 1.6 and
2.6 % of the total national health care expenditures in Western
countries [9, 10]. Many analyses, as well as our own research,
indicate that the majority of expenses are being allocated to
cover direct costs related to the need of hospitalization [1, 7,
11]. Studies by other authors point out that the costs of
productivity loss are higher than the direct costs. A study
conducted in 2002 in the USA concluded that indirect costs
amount to US dollars (USD) 32.4 billion versus 22.7 billion of
direct medical costs [12, 13]. Data mentioned above confirm
that during a global economic crisis, because of the limited
budgets allocated for treatment in individual countries and the
simultaneously growing social needs of a modern and effec-
tive health care, an analysis of treatment costs and offers of
cost-effective solutions optimizing the therapy are necessary
and should be the subject of numerous discussions. Studies
conducted in academic centers guarantee the reliability of
obtained results and the promptness of their publication and
provide wide access to such knowledge and allow academic
centers to be leaders in the development of effective mental
health care. Thus, residents can acquire an exceptional expe-
rience concerning economics of the treatment of schizophre-
nia at the academic level.
Here, we present the economic burden of schizophrenia
treatment in Poznan (Poland) and Lviv (Ukraine) and compare
the percentage of each component of total cost. We compare
treatment schedules and present potential differences in eco-
nomic availability of innovative medicines. Our analysis will
be useful not only for health care decision makers but also for
clinicians and residents from academic centers and could
contribute to academic leadership in terms of acquiring and
spreading knowledge. The examination of the costs of schizo-
phrenia in these countries may lead to the cost-effective treat-
ment of schizophrenia in the long run. In addition, the analysis
suggests evidence-based solutions that may contribute to the
improvement of treatment efficacy while reducing direct and
indirect costs in the long term. Furthermore, it is important to
consider that inpatient care is covered by the public insurance
in both countries. Despite this, patients from Ukraine are
frequently obligated to buy their own innovative medicines
during hospitalization because of insufficient hospital bud-
gets. Such limitation in the access to new generations of
neuroleptics and the lack of a reimbursement system in out-
patient care may contribute to the lack of compliance and
generally, to worse results of schizophrenia treatment.
Although Ukrainian psychiatric hospitals provide 47,000
beds, only a few of them offer comprehensive treatment with
well-organized, non-pharmacological care [14]. Although in
Poland, psychiatric clinics provide 32,000 beds [1], there are
far more opportunities for special social training,
psychoeducation, and other forms of non-pharmacological
treatment. Also important, in Poland, in 2009, there were
133 outpatient psychiatric wards [1]. This way of treatment
is still being developed, but the scope of the progress of
community psychiatry is still insufficient and requires an
urgent and substantial reformulation. In Ukraine, community
care is in worse condition [14], but due to some efforts of
the Ukrainian Psychiatric Associations and international
cooperation between Ukrainian psychiatrists and experts
from western countries, community psychiatry is being con-
sidered as the important point of comprehensive treatment
of schizophrenia. Moreover, initiatives like Psychiatric
Summer School Ukraine–Poland–Germany can lead to the
improvement of psychiatric care, especially in middle- or low-
income countries. Such events, supported by governments, are
aimed to provide a forum for sharing practice in the development
of mental health service in these countries, and academic centers
are included in the study and are intended to contribute to
increasing the cognizance about state-of-the-art mental health
care services. It confirms the need of progress of psychiatric care
both in Poland and Ukraine, and therefore, academic hospitals
could be the driving forces behind beneficial solutions, which
are innovative and applied in numerous countries. Although the
development of psychiatric care requires financial support, men-
tal health should be considered as an investment, not only a cost.
However, in both countries analyzed in this study, psychiatric
care is underfunded. Thus, knowledge acquired by residents
concerning economics and the cost of inpatient care of mental
disorders may lead to the awareness of the need to optimize the
funding of treatment of schizophrenia among future mental
health decision makers.
In Brazil, as in Poland, expenditure on mental health in
relation to the total health budget has been reduced [12, 15]. In
South America, there was a decrease in funding of patients
with mental illness from 5.8 to 2.3 % [12, 15], whereas in
Poland, a decrease was observed from 3.7 % in 2000 to
3.29 % in 2010 [1]. Such a trend makes inpatient care in
Poland under-financed from the state budget, which leads to
the debt of health care facilities. Calculations indicate that the
National Health Care Fund in Poland covers an average of
only 80 % of costs incurred by the mental health care institu-
tions [1]. Similar results were obtained in our own study. The
hospital from Poznan received financial support for only up to
75 % of the total costs generated by the analyzed group of
patients. The value of a budgetary support was zloty (PLN)
165 per person per day, and it was not sufficient to cover needs
(PLN 212 for women and PLN 225 for men without the costs
of medicines and diagnostic tests) of the hospital in Poznan.
This amount of money was decreasing to PLN 80.85 per
person per day for each day of a hospitalization exceeding
70 days. It confirms the need for an urgent modification of the
mental health care founding system in Poland and for an
increase of the allocated expenditure. In the UK, spending
on mental health treatment in the years 2002–2006 increased
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from 3.4 billion to 4 billion pounds [12, 16]. The UK’s policy
conforms to the objectives of the European Union, where it is
emphasized that impaired mental health is a source of addi-
tional costs and burdens for the state [2]. People responsible
for the funding and organization of the health care in many
countries should seek to replicate the UK model, where the
total costs of schizophrenia treatment were estimated at 6.7
billion pounds annually and direct costs amounted to 2 billion
pounds [17]. A similar discrepancy between direct costs and
indirect costs was observed in the population of South
Korea, where direct costs amounted to USD 540 million
compared to USD 3.2 billion of total costs [11]. In
Smark’s study [18] conducted in Australia, indirect costs
were two times higher than direct costs, but in Germany,
indirect costs of schizophrenia treatment constituted to
87 % of total costs [7, 19]. The high costs of schizo-
phrenia treatment are confirmed in the analysis carried
out in India by Grover et al. [20, 21]. The scope of
economic burden of schizophrenia confirms that analyses
concerning the costs of that disorder are useful and valid.
Therefore, every way of treatment, which in a long run
will contribute to the improvement of effectiveness of
treatment of schizophrenia and will lead to the expected
reduction of costs associated with schizophrenia, should
be treated as a priority by people responsible for psychi-
atric care and for a proper education of residents aware
of the importance of economics related to mental health
care.
Material and Methods
The study concerns the results of pharmacoeconomic analysis
of the costs of inpatient treatment in adult patients hospitalized
in Karol Jonscher Hospital of Poznan University of Medical
Sciences (Poland) and in the Psychiatric Hospital of Lviv
National Medical University (Ukraine). The inclusion criteria
were as follows: adulthood of patients of both sexes; schizo-
phrenia diagnosed on the basis of the International Classifica-
tion of Diseases, Tenth Revision (ICD-10); and hospitalization
started and completed between January 2010 and January
2011. Patients were excluded from the study if the hospitali-
zation ended with the patient signing out himself/herself or
having a different time period for the hospitalization. In the
study, 307 hospital records were analyzed: 127 in Poznan and
180 in Lviv. According to the criteria of the study, 108 hospital
records were included: 50 in Poland (25 women and 25 men)
and 58 in the Ukraine (33 women and 25 men). Permission to
analyze patient records was obtained from hospital decision
makers in Poznan and in Lviv and from the previous approval
of the proper Bioethics Committee. The study conforms with
the Act on Protection of Personal Data. Patients were treated
anonymously, and each hospital record was analyzed in
collaboration with the psychiatrist involved in the study. Fur-
thermore, each sample can be considered as representative for
both countries, because analyzed hospital records concerned a
wide range of adult patients. Besides, both cities are known to
be quite huge medical and social centers, which gather pa-
tients from the whole region.
Necessary sensitive information concerning patient
metrics, hospitalization length, medicines used, conduct-
ed diagnostic tests, and relapses was gathered and stored
in a way to ensure its safety and confidentiality. Data
concerning hospital procedures used, data from the hos-
pital formulary, and the price list of diagnostic tests were
obtained from the hospital accounting departments. The
cost was counted for hospital stay, pharmacotherapy, and
diagnostic tests separately, and subsequently obtained
amounts were added, obtaining the total cost of inpatient
care. The cost per day is used in calculating costs of the
inpatient care of schizophrenia. In Poznan a cost per day
(without medicines and diagnostic tests) is PLN 225
(euros (EUR) 55.28) for women and PLN 212 (EUR
52.09) for men. In Lviv, a cost per day is hryvnia
(UAH) 135.30 (EUR 12.82) regardless of the sex of the
patient. Cost of stay was obtained by multiplying the
length of stay of patient by the cost per day. Medicine
prices from 2011 come from the wholesale price list,
which, because of the frequent need for individual med-
icines purchased by patients in the Ukraine, is to ensure
comparability of the cost of drug therapy among ana-
lyzed countries. Moreover, costs covered individually by
Ukrainian patients were included in the pharmacotherapy
cost calculation, because these costs are also an integral
part of inpatient care. In order to calculate the cost of
pharmacotherapy, the exact amount of used medicines
was calculated, and then it was converted to the mone-
tary values resulting from the full price of medicines
packages, whereas the cost of diagnostic tests was cal-
culated by adding values of performed tests.
Moreover, money values were converted from the PLN
and from the UAH to the European currency on the basis of
the average euro exchange rate published by the National
Bank of Poland (NBP) on October 9, 2012 (EUR 1=PLN
4.07; EUR 1=UAH 10.55). Monetary values presented in
the study are a rounding of calculated amounts, which
results from the conversion of monetary units into the
common European currency.
Statistics
The data are shown as mean values ± SEM. The data distri-
bution pattern was not normal (unlike Gaussian function).
Statistical analyses for age in years and hospitalization were
carried out using the nonparametric Kruskal-Wallis test for
unpaired data.
Acad Psychiatry (2015) 39:165–173 167
Results
In the analyzed group of patients from Poznan, the average
age was 33.62 years, whereas patients from Lviv were almost
6 years older (39.26 years) (see Table 1). Statistical difference
between Poznan and Lviv was observed (p=0.0242). The
average length of hospitalization of the patients from Poznan
was x=54.64 days, and in Lviv, x=38.43 days, and statistical
difference between Poznan and Lviv was observed
(p=0.0006). Women from the Polish center were hospitalized
22 days less than men, using 1,091 and 1,641 hospital days,
respectively. In Lviv, however, menwere hospitalized 6.5 days
fewer than women. In Poland, in relation to women, the
shortest and the longest hospitalization lasted 20 and 89 days
and, among men, 25 and 116 days, respectively. Meanwhile,
in Lviv, these indicators are 10 and 90 days in the female
group, and 13 and 64 days among men.
The analyzed group of Polish patients hospitalized for a
total number of 2,732 days generated costs of stay at the value
of PLN 593.367 (EUR 145,790.42), corresponding to
90.79 % of the total calculated costs in Poznan (see Table 2).
Women proportionally to hospital days used (1,091) generated
a cost of PLN 245,475 (EUR 60,313.27), and men, of PLN
347,892 (EUR 85,477.15). The cost of hospitalization of
patients from Lviv is UAH 301,583.5 (EUR 28,586.11), cor-
responding to 92.38 % of the total calculated costs in Lviv.
Women’s hospitalization cost is UAH 183,872.5 (EUR
17,428.67), and men’s hospitalization cost is UAH 117,711
(EUR 11,157.44). These amounts point to the scale of finan-
cial resources allocated to provide effective schizophrenia
treatment. Considering the fact that in Poland, approximately
30,000 people [15] are hospitalized annually in psychiatric
hospitals and assuming the value of medical procedures and
the values of hospitalization calculated in the study and then
converting them to the number of people treated in psychiatric
hospitals, the costs associated with the stay of patients in
Polish hospitals are a burden on the state budget amounting
to PLN 350 million.
The pharmacotherapy cost of patients treated in Poznan
was PLN 43,114.33 (EUR 10,593.20), corresponding to
6.60 % of the total calculated costs, and in Lviv, it was UAH
20,975.93 (EUR 1,988.24), corresponding to 6.3 % of the
total calculated costs. In Poznan, women’s pharmacotherapy
cost was PLN 16,073.72 (EUR 3,949.32), and men’s pharma-
cotherapy cost was PLN 27,040.61 (EUR 6,643.88). In Lviv,
these costs were women UAH 14,515.68 (EUR 1,375.89) and
men UAH 6,460.25 (EUR 612.35).
Diagnostic tests in Poznan accounted for 2.61 % and in
Lviv for 1.19 % of the total costs (Figs. 1 and 2). In Poznan,
the cost of diagnostic tests for women was PLN 6,150 (EUR
1,511.06) and for men, PLN 10,897 (EUR 2,677.40). In Lviv,
it was UAH 2,012.71 (EUR 190.77) for women and UAH
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The total cost of treatment of 50 patients with schizophre-
nia (hospitalization + pharmacotherapy + diagnostics tests) in
Poznan was PLN 653,528.33 (EUR 160,572.08), and per
patient it was PLN 13,070.57 (EUR 3,211.44). In Lviv, the
total cost of treatment of 58 patients was UAH 326,452.55
(EUR 30,943.37), and per patient, it was UAH x=5,628.5
(EUR 533.5).
Interesting data come also from the analysis of the
prescribed pharmacotherapy. Patients in Poznan were
treated with all generations of antipsychotics. Of other
medicines, olanzapine was administered to 64 % of pa-
tients, long-acting risperidone to 12 %, and aripiprazole
to 32 % of patients. In Lviv, patients received mainly
first-generation antipsychotics or older atypical neurolep-
tics, whereas olanzapine, long-acting risperidone, and
aripiprazole were administered to 1.72, 0, and 0 % of
patients, respectively. Haloperidol was the most popular
medicine in Lviv, and 36.21 % of patients obtained this
neuroleptic. In Poland, patients were likewise treated
with haloperidol, but each patient obtained atypical neu-
roleptics concurrently. In Lviv, some patients were treat-
ed only by haloperidol or in combination with different
typical neuroleptics like chlorpromazine, which was not
used in Poznan. Among newer neuroleptics, the most
frequently used medicines in Lviv were clozapine
(36.21 % of patients) and risperidone (17.20 % of
patients).
Apart from the analysis of pharmacotherapy used, the
appraisal of the frequency of schizophrenia relapses within
the last 10 years provides interesting data. In the range be-
tween 0 and 3 hospitalizations, there were 23 patients in
Poznan and 12 in Lviv, whereas in the range from 4 to 7
inpatient stays, there were 11 patients in the Polish center,

















Hospital stay Diagnosc tests Medicines
Men
Women
Fig. 1 Cost of the inpatient care
of schizophrenia in Lviv (Euro).
Source: based on results of our
own studies
Table 2 Treatment costs in Poznań and in Lviv (EUR)
Total Poznań Lviv
Women Men Overall
(% of total costs)
Women Men Overall
(% of total costs)
Women Men Overall
(% of total costs)
Hospitalization cost













































































Source: based on results of our own studies
Acad Psychiatry (2015) 39:165–173 169
hospitalizations within the last 10 years, a significant differ-
ence was observed in both analyzed centers. In Poznan, there
were 16 patients, but in Lviv there were 27 patients.
Discussion
The calculation of costs associated with schizophrenia may
significantly differ among countries. There are still a few,
e s pe c i a l l y conce r n i ng l ow - i n come coun t r i e s ,
pharmacoeconomic analyses presenting a common trend of
results obtained by different research groups. The main reason
of discrepancies in the analogous analyses can be economic
availability of modern pharmacotherapy to patients, the lack
of support in the form of non-pharmacological therapy for
patients and their families, and, above all, different health care
systems and different state budget expenditures for treatment
of mental disorders. In Ukraine, patients inmany cases have to
buy modern medicines, also during hospitalization, on their
own. The original brand of olanzapine (5mg×28 tablets) costs
approximately EUR 100 in the Ukraine and, like long-acting
risperidone, which in Ukraine costs between EUR 125 and
180, is not reimbursed there. In Poland, patients receive these
medicines for free during hospitalization. In outpatient care
and in accordance to the notice of the Polish Minister of
Health of December 21, 2012, these medicines cost, after
reimbursement, EUR 0.79 (long-acting risperidone
37.5 mg×1 syringe) and EUR 10.74 (original olanzapine
5 mg×28 tablets). Moreover, in addition to the differences in
price and in the way of health care funding, Ukrainian citizens
have significantly limited economic access to pharmacother-
apy compared to Polish patients. It is related to the average
earnings of residents of the analyzed countries. In Poland, in
January 2012, the average salary was approximately net to
EUR 660, and in Ukraine, it was about EUR 225. Because of
the system of funding and the organization of psychiatric care,
patients in Poland are treated with a wider range of atypical
neuroleptics. However, due to economic reasons, Ukrainian
patients are obligated to use older antipsychotic medicines.
Some studies have indicated that older neuroleptics may be as
effective as atypical antipsychotics. The CATIE study con-
ducted by Lieberman et al. [22] showed that there were no
relevant discrepancies in efficiency between the first-
generation drug perphenazine and newer medicines. Howev-
er, it seems that there are also some limitations of the CATIE
study, including the limited amount of conventional medicines
taken into consideration and relatively low dosing of medi-
cines used [23]. Moreover, Jarema et al. found better efficacy
and safeness of atypical olanzapine in relation to the perphe-
nazine [24]. The CATIE study has not included medicines like
haloperidol, which in the opinion of the authors of CATIE, is
rarely used. However, presented results and the analysis con-
ducted by Daltio et al. [12] show that haloperidol is still a
frequently used medicine. In spite of the fact that new anti-
psychotics are comparable in efficacy to older brands of
neuroleptics, their better tolerability and less extrapyramidal
side effects [5, 24] can contribute to the better compliance,
which is an important factor of rehospitalization rates and
costs of inpatient care concurrently [25]. Although the use of
atypical antipsychotics could result in the current increase of
the total cost of schizophrenia treatment, their effectiveness
may pay off in fewer side effects of pharmacotherapy, better
compliance, and reduced hospitalizations. Therefore, more
expensive drugs could be cost-effective for society in the long
term [5, 7]. Such results could also contribute to the more
effective teaching of residents, providing them food for
thought about the importance of economic considerations
and the cost of inpatient care and proper funding of many
dimensions of the treatment of schizophrenia.
The lack of reimbursement system, limited funds of Ukrai-
nian patients and their families, and significantly higher prices
of atypical neuroleptics in comparison to the Polish pharma-
ceutical market are probably the main reasons of the observed
discrepancies in the number of patients treated with
olanzapine, long-acting risperidone, and aripiprazole. Despite
this, the observed differences in relation to costs of schizo-
phrenia treatment in Poznan as compared to Lviv are not a
















Hospital stay Diagnosc tests Medicines
Men
Women
Fig. 2 Cost of the inpatient care
of schizophrenia in Poznan
(Euro). Source: based on results
of our own studies
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European countries, discrepancies in the cost of treating pa-
tients suffering from schizophrenia were also presented [26],
for example, with a 12-fold discrepancy between centers in
Spain and in Switzerland. Therefore the sixfold difference
between Poznan and Lviv is not alarming, because the per-
centage of each component of the total cost was similar in the
analyzed centers, and the discrepancy is quite proportional to
the dissimilarity in the cost per day in both cities. As in other
studies [27], in our study the difference was mainly related to
the different organization and funding of medical care, and
therefore results of some research could differ significantly.
In France, Rouillon et al. assessed that the total direct costs
of schizophrenia treatment were FRF 12 billion [7, 28]. In the
opinion of Meerding et al., costs of schizophrenia treatment in
the Netherlands amounted to NLG 800 million [7, 29]. The
study of Goeree et al. demonstrated that direct costs of schizo-
phrenia amounted to 1.12 billion Canadian dollars versus 2.4
billion of total costs spent on the treatment of schizophrenia
[7, 30]. It is estimated that the costs of medicines used in
patients with schizophrenia in developed countries (Germany,
Italy, Canada) amount from 1 to 9% of total direct costs [1, 7].
Results obtained in our own study confirm this trend. In
Poznan, pharmacotherapy accounted for 6.60 %, and in Lviv,
6.43 % of total costs. However, the study of Suleiman et al.
conducted in Nigeria showed that costs of antipsychotic med-
icines accounted for 53 % of total direct costs [7, 31].
Our study confirms the importance and profitability of
investment in innovative and comprehensive treatment. Pa-
tients treated in Poznan with the use of a wider range of
innovative neuroleptics and covered by more widespread
treatment in comparison to patients from Lviv were charac-
terized by fewer relapses of schizophrenia within 10 years
since the beginning of the analysis. Therefore, in spite of the
single amelioration in expenditures related to the embrace-
ment of the broadest amount of patients with modern and
complex therapy, it will contribute to the reduction of hospi-
talizations and simultaneously costs of schizophrenia in the
long run.
Such analyses and obtained results confirm the need of
education of residents, who will be aware of clinical and
economic facets, during times of limited resources that deter-
mine an expected improvement and development of the treat-
ment of mental disorders. Thus, residents ought to take part in
additional courses concerning costs in mental health, and
results of economic analyses should encourage authorities
responsible for developing curricula and syllabuses to the
implementation of updated educational programs that are
aimed to provide useful and innovative knowledge. During
lectures or clinical courses, residents should be taught about
the economic differences between neuroleptics also in relation
to the cost-effectiveness of used medicines and non-
pharmacological treatment. It will contribute to the awareness
of future clinicians or health care decision makers about the
importance of comprehensive treatment, which in spite of the
inevitable investment, will lead to significant savings in the
long run. Besides, residents should be presented with the
knowledge about the cost of inpatient care from hospital
records. Therefore, it seems interesting to introduce in hospital
records obligatory information about general costs of inpatient
care and about individual components, like cost of pharmaco-
therapy. It will allow residents to compare both clinical and
economic effectiveness of applied therapy.
The increase of expenditures on modern pharmacotherapy
in Ukraine, for instance, by a wider availability of innovative
medicines and by reimbursement of atypical neuroleptics,
could contribute to the reduction of total costs of schizophre-
nia treatment in the long term. Experts believe that access to
innovative neuroleptics must not be a privilege—it should be
a right for every single patient [1]. The cost-effectiveness of
using atypical neuroleptics is confirmed by results of
pharmacoeconomic analyses, which indicate that therapy with
innovative medicines is generally cheaper than therapy with
older generations of antipsychotics [32, 33]. It guarantees
fewer hospitalizations and the cost reduction of side effects
related to treatment with old neuroleptics [1]. In spite of the
huge economic burden associated with schizophrenia treat-
ment, costs can be reduced by implementing solutions like
psychoeducation, which contributes to the improvement of
treatment efficacy. Psychoeducation can also lead to reduction
of rehospitalization rates and can help both patients and their
families to cope with the mental illness in a more effective
way [25]. Apart from that, non-pharmacological interventions
lead to the improvement and support the concept of compre-
hensive treatment also related to early intervention in psychot-
ic disorders [34]. Such trainings in community care are also a
great chance for a better social functioning of people with
mental disorders and for their successful comeback to the
labor market. Ergotherapy can lead to cost-effective treatment
results in the long run [1]. Therefore creation of sheltered job
centers should be a kind of a priority in a mental health policy
in Poland and Ukraine. Despite many advantages, there are
still few job centers in Poland. However, in Ukraine, such
community psychiatry almost does not exist, mainly due to
the lack of governmental financial support.
In the study conducted by Rummel-Kluge et al. [25], the
authors found that an increase in the number of patients in-
cluded in such non-pharmacological therapy can contribute to
the reduction in the duration of hospitalization, and as a result
of saved hospital days, it can contribute to the reduction of
direct costs by EUR 150 million [25]. Significant savings can
be expected also in Poland and in Ukraine. As it is presented in
Figs. 1 and 2, the cost of the patient’s hospital stay is the most
important burden in the group of direct costs. Therefore, every
effort leading to a reduction in the duration of hospitalization
should be treated as a priority. Psychoeducation, as a cost-
effective part of a comprehensively understood treatment of
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mental disorders, is presented also by Shimodera et al. [35].
Fewer hospitalizations also create a chance for even partial
recapture of productivity among patients and their health care-
givers who, according to an analysis by Chang et al. [11], were
responsible in South Korea for indirect costs amounting to
US$ 132 million and related to the productivity loss [11]. It
should be pointed out that apart from the source of income,
work for patients during remission has an important psycho-
logical function and affects the course of their disorder. Studies
confirm the correlation of patients’ social condition deteriora-
tion with a more severe course of schizophrenia [1, 36];
therefore, every form of protected employment should contrib-
ute to a reduction of schizophrenia costs and to a better func-
tioning of patients suffering from schizophrenia in the psycho-
social dimension.
Governments of every country and people responsible
for the budgets allocated for mental health should strive to
increase financial outlays for modern and comprehensive
treatment of mental disorders. In a long-term perspective,
the invested money will benefit in significant savings.
Besides, patients who require rarer and shorter hospitaliza-
tions enjoy a better quality of life, they are characterized by
an easier return to social functions performed before the
illness, and they are more successful in seeking solutions
that allow them to regain their productivity lost due to the
illness. Such an image is consistent with the strategy devel-
oped by WHO experts [2], who emphasized the need for a
holistic approach promoting mental health, preventing
mental disorders, and limiting the social stigma of a person
with psychiatric disorder.
The present study has a few limitations: the time horizon of
the study could be extended, and the sample size could be
larger. Inclusion of younger patients as well could lead to an
interesting comparison of pharmacotherapy schedules and their
efficacy in teenaged and adult groups of patients. The analysis
of indirect costs could be an interesting development of such
research. Although Poland and Ukraine have different health
care systems and there are economic discrepancies between
these countries, this study is an interesting source of data
concerning treatment schedules and costs of inpatient care of
schizophrenia. The study concerns also drawbacks of the health
care system in both academic centers; thus, residents from these
centers will consider future pharmacoeconomic facets of ther-
apy both from academic and clinical perspectives and in po-
tential perspective of people responsible for effective mental
health care. However, further studies are still necessary for a
better estimation of schizophrenia. Conducting such analyses in
academic hospitals will allow academic leadership, and these
hospitals could be a source of governmental support, due to
reliable results of studies conducted in academic centers. On
that basis, graduated residents as future health care decision
makers, clinicians in smaller hospitals, or lecturers of subse-
quent generations of pupils could apply this unique knowledge.
Schizophrenia generates huge direct costs, which differ
between study centers in particular because of different sys-
tems of mental health care funding. In Poznan, cost of inpa-
tient care turned out to be six times higher than in Lviv.
Despite this fact, the percentage of each component of the
total cost was similar in the analyzed centers. Medicine prices
significantly differ between the analyzed countries, and there-
by, economic availability of a specific pharmacotherapy can
be limited and can affect direct and indirect costs and patients’
quality of life. Comprehensive treatment is cost effective, and
patients treated with a wider range of atypical neuroleptics and
with more severe non-pharmacological treatment were less
hospitalized. Economic availability of innovative and effec-
tive treatments should be equalized by actions aimed at low-
ering drug prices or their adjustment to the patients’ affluence.
Moreover, innovative and cost-effective pharmacotherapy
should be reimbursed because it should provide a more effec-
tive health care also in economic terms. Although investment
in the innovative and comprehensive treatment could amelio-
rate a critical part of the costs of schizophrenia, it would be
cost-effective in the long run nonetheless.
Implications for Educators
• Academic educators are responsible for interdisciplinary teaching of
residents to be thoughtful also about the economics and cost of
inpatient care.
• The introduction of mental health economy to educational programs
and curricula will allow residents to acquire suitable experience at the
academic level and contribute to awareness about the importance of
analyses of cost of inpatient care and about the ways of cost-effective
treatment of schizophrenia in the long run.
• Academic hospitals could be a leader of the development and
spreading of cost-effective therapeutic solutions that could have im-
portant implications for funding of psychiatric care and for residents
who will be responsible for a profitable treatment.
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